Kamada Is Bringing Relief To Those With Rare And Serious Conditions
By Johnny Rice Benzinga
DETROIT, MICHIGAN - April 16, 2025 ( NEWMEDIAWIRE ) - Amir London, CEO of Kamada Pharmaceuticals (NASDAQ: KMDA), was recently a guest on Benzinga's All-Access.
Kamada is a global biopharmaceutical company with a portfolio of assets indicated for rare and serious conditions. The company reports it is a leader in the specialty plasma-derived field, focused on diseases with limited treatment alternatives.
Mr. London was on the program to discuss exciting developments in the company's development pipeline as well as Mr. London's strategy for M&A.
Watch the full interview here:
https://youtu.be/qcXRR2EqZx0
Featured photo byHal GatewoodonUnsplash.
This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.
This content was originallypublished on Benzinga. Read further disclosureshere.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Former head trader of Denver-based investing company pleads guilty to insider trading
DENVER (KDVR) — A Connecticut man pleaded guilty to an insider trading charge on Friday for actions he took while employed at Denver-based firm Irving Investors. Ryan Squillante, 40, of Weston, Connecticut, was employed as the head of equity trading at Irving Investors at the time of the offense, according to the U.S. Attorney's Office for the District of Connecticut. While there, he received 'material non-public information' about some publicly traded companies. Australian hacker sentenced in May arrested by HSI Denver, faces deportation Prosecutors say that Squillante used MNPI on 15 different occasions between August 2022 and May 2023 for his own benefit, profiting about $220,912 from the transactions, according to the attorney's office. The U.S. Attorney's Office for the District of Connecticut provided an example of one of the times Squillante reportedly received MNPI about a clinical-stage biopharmaceutical company called Praxis Precision Medicines. Praxis is traded on the NASDAQ. The prosecutors said that between Feb. 27, 2023, and March 2, 2023, Squillante 'sold short' over 38,000 shares of Praxis for an average price per share of $3.04. On March 3, prosecutors say Squillante announced poor results of the company's drug trial before the market opened. Following that announcement, Squillante 'covered' the same number of shares at an average price of $1.82 per share, making a profit of about $46,421. Squillante pleaded guilty to securities fraud, which has a maximum term of imprisonment of 20 years. He's scheduled to be sentenced on Aug. 29. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
Morning Bid: Markets pin hopes on London trade talks
A look at the day ahead in European and global markets from Rocky Swift Optimism abounds in the markets that the United States and China will reach a rapprochement in London today, after a phone call last week between leaders of the world's two largest economies turned down the heat on their protracted rift over trade. Both sides have strong incentives to ratchet down the rhetoric and find agreement as their economies remain tightly linked, although U.S. President Donald Trump has shown interest in decoupling them. The market reacted favourably on Friday to U.S. jobs data that showed less of a slowdown than feared, temporarily easing concerns about the trade war's fallout. But that was counterbalanced today when China's dour producer price data added to evidence that the spat is taking its toll. Asian shares rebounded sharply on Monday, reacting to Friday's exuberance on Wall Street. Equity futures pointed to a slightly lower open in Europe, while U.S. stock futures, the S&P 500 e-minis, slid 0.2%. On the trade front, representatives from the U.S. and China, due to meet at a still undisclosed location in London, will attempt to revive a preliminary trade agreement reached in Geneva last month. Trump is threatening to impose triple-digit tariffs on Chinese goods, while Beijing's key leverage is its near stranglehold on rare earth minerals that are critical to many high-tech sectors. Perhaps persistence is the key. Japan's chief trade negotiator Ryosei Akazawa is planning a sixth round of talks in Washington this week, Kyodo News reported. The economic and earnings slate is practically empty today. The next major figures to watch out of the U.S. will be inflation data on Wednesday, followed later in the week by producer price figures, weekly jobless claims and the University of Michigan report on consumer sentiment. The Fed is in a blackout period ahead of its June 18 policy decision. The markets were also keeping an eye on events in Los Angeles, where National Guard troops are facing down protesters demonstrating over Trump's immigration policies. Videos showed part of a major freeway in the city blocked by activists. California on its own is the world's fourth-largest economy, exceeding Japan's gross domestic product, and Trump deployed guardsmen to its biggest city to counteract what the White House described as "chaos, violence and lawlessness". Governor Gavin Newsom called Trump's reaction "the acts of a dictator". Key developments that could influence markets on Monday: - U.S. wholesale inventory data for April. - Mexico reports inflation and producer price data for May. Trying to keep up with the latest tariff news? Our new daily news digest offers a rundown of the top market-moving headlines impacting global trade. Sign up for Tariff Watch here. (By Rocky Swift; Editing by Edmund Klamann) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
an hour ago
- Bloomberg
BOE Risks Repeat of Brexit Pessimism as Growth Signals Diverge
Bank of England rate-setters risk underestimating the strength of the UK economy by placing too much faith in downbeat business surveys over official growth data. Governor Andrew Bailey revealed last week he is putting more emphasis on indicators such as S&P Global's purchasing managers' index, warning that 'we've had more volatile, short-run GDP numbers of late.' However, BOE watchers caution against repeating the error made after the 2016 Brexit referendum, when officials eased policy in response to a sharp downturn registered in surveys.
